Compare JFIN & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JFIN | EDIT |
|---|---|---|
| Founded | 2011 | 2013 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 223.6M | 206.0M |
| IPO Year | 2018 | 2016 |
| Metric | JFIN | EDIT |
|---|---|---|
| Price | $4.70 | $3.35 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $4.92 |
| AVG Volume (30 Days) | 85.2K | ★ 1.5M |
| Earning Date | 06-03-2026 | 05-11-2026 |
| Dividend Yield | ★ 17.70% | N/A |
| EPS Growth | N/A | ★ 37.50 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $31,937,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1.35 | ★ N/A |
| Revenue Growth | N/A | ★ 132.64 |
| 52 Week Low | $3.70 | $1.23 |
| 52 Week High | $18.70 | $4.54 |
| Indicator | JFIN | EDIT |
|---|---|---|
| Relative Strength Index (RSI) | 43.95 | 76.81 |
| Support Level | $3.70 | $3.32 |
| Resistance Level | $7.22 | $3.58 |
| Average True Range (ATR) | 0.30 | 0.22 |
| MACD | 0.07 | 0.08 |
| Stochastic Oscillator | 75.38 | 83.74 |
Jiayin Group Inc is China's technology service group. It is an enterprise engaged in technological innovation services. It is committed to using big data, cloud computing, artificial intelligence and other technologies to connect consumers and financial institutions in consumption scenarios so that every user can enjoy efficient and convenient technology services. The company has engraved technological innovation into the company's development genes since its establishment, adheres to the dual drive of digital plus technology, and focuses on building a cloud service platform and intelligent risk control system with big data drive as the core concept.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.